The online version of this article (doi:10.1186/s12890-015-0138-4) contains supplementary material, which is available to authorized users.
Mike Chambers is a GSK employees and owns GSK stock. Funding was provided by GSK.
DAS and JT contributed to the conception and design, acquisition of data and data analysis and interpretation. BW, NH, MC, PC and BC contributed to the conception and design and the data analysis and interpretation. JC contributed to the conception and design and acquisition of data. All authors read and approved the final manuscript.
Increasing evidence suggests pharmacological treatments may impact on overall survival in Chronic Obstructive Pulmonary Disease (COPD) patients. Individual clinical trials are rarely powered to detect mortality differences between treatments and may not include all treatment options relevant to healthcare decision makers.
A systematic review was conducted to identify RCTs of COPD treatments reporting mortality; evidence was synthesised using network meta-analysis (NMA). The analysis included 40 RCTs; a quantitative indirect comparison between 14 treatments using data from 55,220 patients was conducted.
The analysis reported two treatments reducing all-cause mortality; salmeterol/fluticasone propionate combination (SFC) was associated with a reduction in mortality versus placebo in the fixed effects (HR 0.79; 95 % Crl 0.67, 0.94) but not the random effects model (0.79; 0.56, 1.09). Indacaterol was associated with a reduction in mortality versus placebo in fixed (0.28; 0.08 to 0.85) and random effects (0.29; 0.08, 0.89) models. Mean estimates and credible intervals for hazard ratios for indacaterol versus placebo are based on a small number of events; estimates may change when the results of future studies are included. These results were maintained across a variety of assumptions and provide evidence that SFC and indacaterol may lead to improved survival in COPD patients.
Results of an NMA of COPD treatments suggest that SFC and indacaterol may reduce mortality. Further research is warranted to strengthen this conclusion.
Additional file 1: Stastical Methods. (PDF 376 kb)12890_2015_138_MOESM1_ESM.pdf
Additional file 2: Table S1. Reasons for excluding full publications. Table 2. Risk of bias results. Table S3. Fixed effects network meta-analysis results. Hazard ratios compared to placebo (95% Credible Intervals). Table 4. Placebo mortality by treatment arm. (PDF 352 kb)12890_2015_138_MOESM2_ESM.pdf
World Health Organization. The top 10 causes of death: Fact Sheet No. 310. 2014; http://www.who.int/mediacentre/factsheets/fs310/en/.
Institute for Quality and Efficiency in Health Care (IQWiG). General Methods 4.0 . 2011 2011.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2014; 2014.
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;30(20):3105–24. CrossRef
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions v.5.1.0. The Cochrane Collaboration . 2011. www.cochrane-handbook.org.
Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD. N Engl J Med. 2013
Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual: Version 1.4. Cambridge: MRC Biostatistics Unit. 2003; 2003.
Spiegelhalter D, Best N, Carlin B, Van der Linde A. Bayesian Measures of model complexity and fit (with discussion). J Royal Statistical Soc. 2002;64(4):583–639. CrossRef
Brooks S, Gelman A. General Methods for Monitoring Convergence of Iterative Simulations. J Comput Graph Stat. 1998;7(4):434–55.
Wise R, Connett J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902–9. CrossRef
Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–65. PubMedPubMedCentralCrossRef
Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;2:273–9. CrossRef
Zhong N, Zheng J, Wen F, Yang L, Chen P, Xiu Q, et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research & Opinion. 2012;28(2):257–65. CrossRef
Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23. PubMedCrossRef
Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Med. 2007;8:93.
Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: Results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000. PubMedCrossRef
- Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis
David A Scott
Juliette C Thompson
James F Clark
Bartolome R. Celli
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II